In addition, to assess Ag-specific Th cell responses, IL-6, IL-17, and TGF-β were measured in cell supernatants from lymphocytes restimulated with F1- and V-Ag by sandwich ELISA, as were IFN-γ and IL-10 (Fig. 8B). Although TGF-β was not detected (data not shown), Ag-specific IL-6 and IL-17 production was enhanced significantly, as well as IFN-γ and IL-10. For the i.m. immunization study, lymphocytes from spleens, HNLNs, and PLNs, which were obtained from each two DNA-vaccinated mice at 14 wks, were restimulated with F1-Ag, V-Ag, or media for 2 days (Fig. 9A). I.m. LTN DNA immunization also showed significantly Doxorubicin supplier Ag-specific enhancement of IFN-γ production, as well as IL-4, IL-5, and IL-10

in both spleens and LNs. In addition, IFN-γ, IL-6, IL-10, IL-17, and TGF-β were also measured in cell supernatants from lymphocytes restimulated with F1- and V-Ag by sandwich ELISA (Fig. 9B). Although TGF-β were not detected (data not shown), Ag-specific IL-6 and IL-17 production was enhanced significantly, as well as IFN-γ and

IL-10. These results suggest that both LTN DNA vaccines primed for Ag-specific T cells, and Th1-, Th2-, and Th17-type cytokines in the i.n.- and i.m.-immunized mice. In this study, to obtain an effective DNA vaccine against pneumonic plague, two DNA vaccines were constructed co-expressing the V-Ag or F1-V fusion protein in combination high throughput screening compounds with LTN DNA as a molecular adjuvant. Since Y. pestis is a facultative intracellular pathogen, Parent and co-workers suggested that plague vaccines should be designed to maximally prime both cellular and humoral immunity for

effective protection [13], [14] and [15]. LTN was selected as a molecular adjuvant because past studies have shown that LTN exhibits both Th1- and Th2-type properties when applied mucosally and parenterally [18], [19], [20], [21], [22], [23] and [24]. LTN is produced by CD8+ T cells, NK cells, and γδ TCR+ IEL, indicating induction of protection immunity against tumors through chemotaxis of T cells and natural killer (NK) cells [32] and [33]. LTN has also been adapted as a molecular adjuvant for development of vaccines against pathogens, including human immunodeficiency virus (HIV) [34] old and avian coccidiosis [35]. For the development of an effective plague vaccine, we tested LTN as a molecular adjuvant against Y. pestis. In this study, the mucosal adjuvant effect by LTN to stimulate protective immunity was not as apparent when given nasally. Although nasal immunization with LTN/βgal DNA vaccine plus F1-Ag did appear to confer improved protection against pneumonic plague challenge, this was not significantly different from any of the vaccinated groups. Likewise, for i.m. DNA-vaccinated mice, protection conferred by the LTN/βgal DNA vaccine was not significantly different from the LTN/V or LTN/F1-V immunized mice. However, these results show that i.m.